NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization574.01 mln
Float8.80 mln
Earnings Date08/12/2026
EPS
0.08
Overpriced
P / E
342
Bubble territory
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-0.68
Highly suspicious
1-Year Forecast
50.00
Transformational upside
Relative Strength
90
/ 100
Top performer
Business Description
Assembly Biosciences is a South San Francisco-based biotechnology company focused on developing new treatments for viral infections, including herpes, hepatitis B, and hepatitis delta virus. The company has several drug candidates at various stages of clinical testing, spanning both injectable and oral treatment options. It works alongside Gilead Sciences under a research and licensing agreement to advance antiviral therapies.
